59 patents
Utility
RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use
28 Dec 23
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene.
Zhi-Ming Ding, Jonathan Van Dyke, Xiaokai Li, Anthony Nicholas, Casi M. Schienebeck, Tao Pei, Zhao Xu, Teng Ai, Susan Phan, Susan Ramos-Hunter
Filed: 9 Mar 23
Utility
Integrin Targeting Ligands and Uses Thereof
21 Dec 23
Xiaokai Li, Tao Pei, Susan Phan, Andrei V. Blokhin
Filed: 9 Mar 23
Utility
Rnai Agents for Hepatitis B Virus Infection
9 Nov 23
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
Filed: 2 Dec 22
Utility
Rnai Therapy for Hepatitis B Virus Infection
9 Nov 23
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Christine I. WOODDELL, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Filed: 21 Dec 22
Utility
Methods for the Reduction of Z-aat Protein Levels
2 Nov 23
Described are methods of reducing liver Z-AAT protein levels in a human subject with a PiZZ genotype of alpha-1 antitrypsin (AAT) by using pharmaceutical compositions that include AAT RNAi agents.
Dawn Christianson, James C. Hamilton, Bruce Given
Filed: 14 Sep 21
Utility
RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
12 Oct 23
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents.
Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
Filed: 22 Dec 22
Utility
Lipid Conjugates for the Delivery of Therapeutic Agents
20 Jul 23
Xiaokai Li, Tao Pei, Teng Ai, Susan Phan, Susan Ramos-Hunter
Filed: 3 Mar 23
Utility
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
4 May 23
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression.
Anthony NICHOLAS, Tao PEI, Zhao XU, Daniel BRAAS, Zhi-Ming DING
Filed: 12 Oct 22
Utility
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
27 Apr 23
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression.
Anthony NICHOLAS, Tao PEI, Zhao XU, Daniel BRAAS, Zhi-Ming DING
Filed: 28 Oct 22
Utility
RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use
19 Jan 23
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a beta-ENaC (SCNN1B) gene.
Anthony Nicholas, Casi M. Schienebeck, Erik W. Bush, Tao Pei, Zhao Xu, Zhen Li, Rui Zhu
Filed: 28 Apr 22
Utility
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
19 Jan 23
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression.
Anthony NICHOLAS, Tao PEI, Zhao XU, Daniel BRAAS, Zhi-Ming DING
Filed: 19 May 22
Utility
Compositions and Methods for Inhibiting Gene Expression of ALPHA-1 Antitrypsin
5 Jan 23
The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference.
Christine I. Wooddell, David L. Lewis, Darren H. Wakefield, Lauren Almeida, Steven B. Kanner
Filed: 8 Jun 22
Utility
RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
5 Jan 23
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Mucin 5AC (MUC5AC) gene.
Erik W. Bush, Anthony Nicholas, Casi M. Schienebeck
Filed: 25 May 22
Utility
RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
5 Jan 23
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression.
Anthony NICHOLAS, Tao PEI, Zhao XU, Daniel BRAAS, Zhi-Ming DING
Filed: 19 May 22
Utility
Trialkyne Linking Agents and Methods of Use
22 Dec 22
Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides.
Zhen Li, Erich Altenhofer, Jeffrey Carlson, Matthew Fowler-Watters, Bo Chen
Filed: 15 Feb 19
Utility
RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use
15 Dec 22
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene.
Anthony Nicholas, Erik W. Bush, David Itiro Kasahara, Casi M. Schienebeck
Filed: 7 Apr 22
Utility
Organic Compositions to Treat HSF1-RELATED Diseases
1 Dec 22
The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
Filed: 6 Apr 22
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
17 Nov 22
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 15 Jun 22
Utility
Methods for the Treatment of ALPHA-1 Antitrypsin Deficiency (Aatd)
29 Sep 22
Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents.
Bruce Given, Dawn Christianson, James C. Hamilton, Zhen Li, Rui Zhu, Christine Wooddell, Tao Pei
Filed: 5 Jun 20
Utility
RNAi Inhibition of Alpha-ENaC Expression
28 Jul 22
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
Filed: 5 Apr 22